Trading update | Diaceutics

Trading update

Diaceutics PLC (AIM: DXRX), a provider of data analytics and implementation services to the global pharmaceutical industry, announces a trading update for the six months ended 30 June 2019.  Trading has continued in line with market expectations and the Company remains well positioned in key markets, underpinned by a strong sales performance.

An increased international footprint has enhanced Diaceutics’ global offering and allowed the Company to acquire new international clients.  The Nexus project is progressing as planned.

All outstanding debt has now been retired from the balance sheet resulting in net cash of £14.0m.

The Group’s interim results are expected to be announced in early September.


Peter Keeling, Chief Executive OfficerVia Walbrook PR
Philip White, Chief Financial Officer
Cenkos Securities plc (Nominated adviser and broker)+44 (0) 20 3861 6630
Callum Davidson / Giles Balleny
Michael Johnson (Sales)
Walbrook PRTel: +44 (0)20 7933 8780 or
Anna DunphyMob: +44 (0)7876 741 001
Paul McManusMob: +44 (0)7980 541 893


About Diaceutics
Diaceutics PLC is a leading diagnostics data analytics and implementation services business for major pharmaceutical companies. The Company, listed on the Alternative Investment Market (AIM) of the London Stock Exchange, is transforming an industry model by enabling pharma to accelerate their market penetration and achieve a better return on new therapies by helping them to revolutionise their patient testing. It does this by providing insights generated from its vast data lake consisting of real time diagnostic testing data gather from clinical laboratories around the world. Diaceutics’ services help pharma to understand and leverage the diagnostic landscape and deploy initiatives that improve patient diagnosis. The Company has experience of more than 300 precision medicine projects and works with more than 30 global pharmaceutical companies. The Company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries.

Latest Blogs

Latest Blogs